PCM
SLDB icon

Prelude Capital Management’s Solid Biosciences SLDB Stock Holding History

Prelude Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-788
Closed -$122K – 2214
2019
Q3 		$122K Buy
+788
New +$89.2K 0.01% 890
2018
Q4 		– Sell
-60
Closed -$42K – 2127
2018
Q3 		$42K Sell
60
-40
-40% -$25.1K ﹤0.01% 1175
2018
Q2 		$53K Sell
100
-232
-70% -$71.4K ﹤0.01% 1107
2018
Q1 		$37K Buy
+332
New +$112K ﹤0.01% 1152

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's SLDB Position: Q4 2019 in Review

Prelude Capital Management sold out of Solid Biosciences (SLDB) in Q4 2019, closing a stake of 788 shares — an estimated $122K sold.

Prelude Capital Management first reported a position in SLDB in Q1 2018 and held it in 4 quarters. The position peaked at $122K in Q3 2019. 69 funds tracked by Wall St. Rank hold SLDB as of Q4 2019.

  • Prelude Capital Management reported no remaining Solid Biosciences position as of Q4 2019 after selling out during the quarter.
  • Prelude Capital Management sold 788 Solid Biosciences shares in Q4 2019, an estimated $122K.
  • Prelude Capital Management first reported a position in Solid Biosciences in Q1 2018 and held it in 4 quarters.
  • Prelude Capital Management's Solid Biosciences position peaked at $122K in Q3 2019.
  • 69 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2019.

Based on Prelude Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.